File Download

There are no files associated with this item.

  • Find it @ UNIST can give you direct access to the published full text of this article. (UNISTARs only)
Related Researcher

조윤경

Cho, Yoon-Kyoung
FRUITS Lab.
Read More

Views & Downloads

Detailed Information

Cited time in webofscience Cited time in scopus
Metadata Downloads

The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer

Author(s)
Dong, LiangZhang, ZhongyuanSmith, KimberlyKuczler, Morgan D.Reyes, DianeAmend, Sarah R.Cho, Yoon-KyoungXue, WeiPienta, Kenneth J.
Issued Date
2020-07
DOI
10.1111/bju.15041
URI
https://scholarworks.unist.ac.kr/handle/201301/31999
Fulltext
https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.15041
Citation
BJU INTERNATIONAL, v.126, no.1, pp.191 - 201
Abstract
Objective To investigate the circulating tumour cells (CTCs) capture abilities of two technologies that are not dependent on cell-surface marker expression: a selection-free platform [AccuCyte(R)-CyteFinder(R) system (Rarecyte)] and a size-based platform [fluid-assisted separation technology (FAST)]. In addition, the combination of the two systems to more completely assess CTCs was investigated. Patients and methods In all, 28 patients with metastatic prostate cancer were included. Two 6 mL peripheral blood samples were taken from each patient at the same time-point. The samples were then subjected to the two different technology platforms in parallel. An additional group of samples was acquired by applying the waste chamber material from the FAST-group tests (flow-through that goes through the FAST filter membrane) to the Rarecyte system for the detection any CTCs that were not captured by FAST. Results The three groups had significantly different putative CTC-positive tests, with positive rates of 29% for Rarecyte, 57% for FAST, and 79% for the combination. We also assessed CTC phenotype: 56.6% of the CTCs were cytokeratin (CK)+/epithelial cell adhesion molecule (EpCAM)-, 3.1% were CK-/EpCAM+, and 40.3% were CK+/EPCAM+. The captured CTCs diameter ranged from 5.2 to 16.9 mu m. The mean CTC size from the FAST waste chamber was significantly smaller. The diameters for each of the phenotypic groups were significantly different. Conclusions These data highlight disparities in the positive rates and enumerated CTC numbers detected by the two techniques. Notably, the combination of the two technologies resulted in the highest CTC-capture rates. Smaller CTCs were more likely to be missed by the FAST as they passed through the filter system. Sizes of CTCs varied with different cell surface marker phenotypes.
Publisher
WILEY
ISSN
1464-4096
Keyword (Author)
circulating tumour cellssize-based separation technologyselection-free technologymetastatic prostate cancer
Keyword
BIOMARKERSSURVIVAL

qrcode

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.